These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8522228)

  • 1. [Clinical effectiveness of Marvelon].
    Marianowski L; Grzechocińska B
    Ginekol Pol; 1995 May; 66(5):294-6. PubMed ID: 8522228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M; Almström E; Högstedt S; Nabrink M
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
    Rekers H
    Acta Obstet Gynecol Scand; 1988; 67(2):171-4. PubMed ID: 2972160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
    Kasule J; Mbizvo M; Makuyana D; Masona D
    Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A clinical trial with the monophasic contraceptive Marvelon].
    Rachev E; Damianov L; Katsarova M
    Akush Ginekol (Sofiia); 1994; 33(3):44-5. PubMed ID: 7793530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women.
    Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B
    Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function.
    Prasad RN; Koh S; Ratnam SS
    Contraception; 1989 Apr; 39(4):369-83. PubMed ID: 2524360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon).
    Ismail MT
    Malays J Reprod Health; 1994 Jun; 12(1):43-8. PubMed ID: 12320338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.